Sherman S - Search Results

1

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.

Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D. Lu T, et al. Among authors: sherman s. J Clin Invest. 2011 Oct;121(10):4015-29. doi: 10.1172/JCI45862. Epub 2011 Sep 12. J Clin Invest. 2011. PMID: 21911941 Free PMC article.

2

Effects of notch signaling on regulation of myeloid cell differentiation in cancer.

Cheng P, Kumar V, Liu H, Youn JI, Fishman M, Sherman S, Gabrilovich D. Cheng P, et al. Among authors: sherman s. Cancer Res. 2014 Jan 1;74(1):141-52. doi: 10.1158/0008-5472.CAN-13-1686. Epub 2013 Nov 12. Cancer Res. 2014. PMID: 24220241 Free PMC article.

3

Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.

Nagaraj S, Pisarev V, Kinarsky L, Sherman S, Muro-Cacho C, Altieri DC, Gabrilovich DI. Nagaraj S, et al. Among authors: sherman s. J Immunother. 2007 Feb-Mar;30(2):169-79. doi: 10.1097/01.cji.0000211329.83890.ba. J Immunother. 2007. PMID: 17471164

4

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Nagaraj S, et al. Among authors: sherman s. Nat Med. 2007 Jul;13(7):828-35. doi: 10.1038/nm1609. Epub 2007 Jul 1. Nat Med. 2007. PMID: 17603493 Free PMC article.

5

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells.

Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Nefedova Y, et al. Among authors: sherman s. Cancer Res. 2007 Nov 15;67(22):11021-8. doi: 10.1158/0008-5472.CAN-07-2593. Cancer Res. 2007. PMID: 18006848

6

Full-length dominant-negative survivin for cancer immunotherapy.

Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Pisarev V, et al. Among authors: sherman s. Clin Cancer Res. 2003 Dec 15;9(17):6523-33. Clin Cancer Res. 2003. PMID: 14695157

7

T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.

Pisarev VM, Kinarsky L, Caffrey T, Hanisch FG, Sanderson S, Hollingsworth MA, Sherman S. Pisarev VM, et al. Among authors: sherman s. Int Immunopharmacol. 2005 Feb;5(2):315-30. doi: 10.1016/j.intimp.2004.10.004. Int Immunopharmacol. 2005. PMID: 15652762

8

Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.

Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, Hanisch FG. Ninkovic T, et al. Among authors: sherman s. Mol Immunol. 2009 Nov;47(1):131-40. doi: 10.1016/j.molimm.2008.09.032. Epub 2008 Nov 12. Mol Immunol. 2009. PMID: 19007994 Free PMC article.

9

Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.

Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemachek C, Ciborowski P, Przedborski S, Mosley RL, Gendelman HE. Benner EJ, et al. Among authors: sherman s. PLoS One. 2008 Jan 2;3(1):e1376. doi: 10.1371/journal.pone.0001376. PLoS One. 2008. PMID: 18167537 Free PMC article.

10

Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses.

von Mensdorff-Pouilly S, Kinarsky L, Engelmann K, Baldus SE, Verheijen RH, Hollingsworth MA, Pisarev V, Sherman S, Hanisch FG. von Mensdorff-Pouilly S, et al. Among authors: sherman s. Glycobiology. 2005 Aug;15(8):735-46. doi: 10.1093/glycob/cwi058. Epub 2005 Apr 6. Glycobiology. 2005. PMID: 15814824

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,119 results

Search Page

Filters